Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAROLYN: Liso-cel in Transplant-Ineligible PCNSL
NCT07015242Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2025
- Primary completion
- Jan 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of lisocabtagene maraleucel in primary central nervous system lymphoma (PCNSL), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-free Survival at 12 months. Started Nov 2025; status: recruiting.
02
Drugs
lisocabtagene maraleucel
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT07015242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07015242.